Jenburkt Pharmaceuticals Ltd — Others, 20-06-2025: AGM/EGM

Jenburkt Pharmaceuticals has announced a board meeting on 18th July 2025 to approve the financial results for the quarter and half-year. The company is proposing a final dividend of ₹18 per share, implying a payout of ₹794.39 lacs from surplus profits. Shri Ashish U. Bhuta is set for re-appointment as the Chairman and Managing Director for a further five years from April 2026, with fixed monthly salary of ₹33 lacs plus commission up to 3% of Profit After Tax for three years. The company’s audited financials show revenue increase of 8% to ₹158.41 Cr, profit after tax up 23% to ₹32.06 Cr, and EPS rose to ₹72.65. Net worth improved by 19% to ₹171.78 Cr. The company operates in pharmaceuticals, focusing on both domestic and export markets. No material related party transactions or regulatory compliance issues reported. The firm continues digital transformation, product launches, and expansion of wellness division, while maintaining robust governance with independent directors and various board committees actively functioning. CSR spend stood at ₹82.84 lacs, exceeding the mandated 2% of average net profit. The company maintains strong internal financial controls, is debt-free with manageable lease liabilities and bank borrowings, and showed improvement in operating and net profit margins for FY 24-25.